Synapse - Irina Ostrovnaya

Results (200)

Clinical validation of a multi-modal Ataraxis AI platform for recurrence prediction in early-stage breast cancer across multiple patient cohorts

Meeting Abstract

Witowski, J.; Choucair, K.; Elayoubi, J.; Chiru, E. D.; Chan, N.; Kang, Y. J.; Howard, F. M.; Ostrovnaya, I.; Schnabel, F. R.; Abdulsattar, W.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Cutaneous toxicity and clinical outcomes with enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma

Meeting Abstract

Arbuiso, A.; Sternschuss, M.; Whiting, K.; Gupta, A.; Huttenlocher Bent, E.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Treatment patterns and clinical outcomes with platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in patients with metastatic urothelial carcinoma

Meeting Abstract

Sternschuss, M.; Whiting, K.; Arbuiso, A.; Gupta, A.; Bent, E. H.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma

Journal Article

Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N. M.; more...
ESMO Open (2025)

Fulltext@MSK | Save

Genetic ancestry-based differences in biomarker-based eligibility for precision oncology therapies

Journal Article

Arora, K.; Suehnholz, S. P.; Zhang, H.; Ostrovnaya, I.; Kundra, R.; Nandakumar, S.; Nissan, M. H.; Brannon, A. R.; Bandlamudi, C.; Ladanyi, M.; more...
JAMA Oncology (2025)

Fulltext@MSK | Save

Transcriptional analysis of bladder cancer histologic subtypes reveals novel drug target heterogeneity

Meeting Abstract

Tallman, J. E.; Kuo, F.; Koll, F.; Alam, S. M.; Basar, M.; Luo, J.; Gao, S. P.; Tang, X.; Yol, C.; Gokturk, G.; more...
Urologic Oncology: Seminars and Original Investigations (2025)

Fulltext@MSK | Save

Higher risk renal angiomyolipomas: Surveillance remains a safe management option

Journal Article

Dawidek, M. T.; Villada, J. S. A.; Vazquez-Rivera, K.; Fuchs, H.; Calderon, L. P.; Eismann, L.; Reese, S. W.; Ganz, M.; Ridouani, F.; Ostrovnaya, I.; more...
Urology Practice (2025)

Fulltext@MSK | Save

Sample site impacts RNA biomarkers for renal cell carcinoma

Journal Article

Eismann, L.; Xie, A. X.; Tang, C.; Knezevic, A.; Ostrovnaya, I.; Kuo, F.; Ari Hakimi, A.; Reznik, E.; Kotecha, R. R.
European Urology (2025)

Fulltext@MSK | Save

Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression

Meeting Abstract

Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC)

Meeting Abstract

Wong, W.; Sherman, E. J.; Kriplani, A.; Michel, L.; Zhi, I.; Hung, T. K. W.; Dunn, L.; Grewal, R. K.; Krishnamoorthy, G.; Ostrovnaya, I.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save